PMS2 and Lynch syndrome: We found that restricting IHC testing to a two-antibody (MSH6 and PMS2) panel would improve cost-effectiveness, but this finding was based on no Lynch syndrome cases failing to display deficient expression for one of these proteins within PETALS, whereas other studies have shown that a two-antibody panel is inferior to a four-antibody panel [35].